Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years

BACKGROUND AND PURPOSE: Pathologic changes in GM have an important role in MS. We investigated the association between SDGM and cortical volume changes and disability progression in early RRMS. MATERIALS AND METHODS: One hundred eighty patients with RRMS had clinical assessment during 5 years and were divided into those with or without SDP at 5 years by the usual definition in treatment trials. The number of available MR imaging scans at various time points was the following: at baseline, 178; and at 6 months, 172; at 12 months, 175; at 24 months, 155; at 36 months, 160; at 48 months, 158; and at 60 months, 162, respectively. Longitudinal changes in cortical, GM, and WM volume were calculated by using the direct method. RESULTS: At 5 years, 90 patients with RRMS experienced SDP and 90 had stable disease. At baseline, patients with SDP had longer disease duration, greater T2-lesion volume, and smaller whole-brain, WM, cortical, and SDGM volume (P < .01). At 5 years, patients with SDP had significantly greater percentage decreases from baseline compared with those without SDP in the volume of the whole brain (P < .0001), cortex (P = .001), GM (P = .003), and thalamus (P = .01). In patients who developed SDP at 5 years and those who did not, mixed-effect models, adjusted for age, disease duration, and change of the treatment status, showed significant interactions between SDP status at 5 years and changes with time in whole-brain, cortical, lateral ventricle (all P < .001), thalamus (P = .006), and total SDGM (P = .0095) volume. CONCLUSIONS: SDP is associated with progression of cortical, central, and thalamic atrophy in early RRMS during 5 years.

[1]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[2]  Stephen M. Smith,et al.  Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm , 2001, IEEE Transactions on Medical Imaging.

[3]  M. Filippi,et al.  Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.

[4]  Andrea Cherubini,et al.  Aging of subcortical nuclei: Microstructural, mineralization and atrophy modifications measured in vivo using MRI , 2009, NeuroImage.

[5]  R. Zivadinov,et al.  Advances in understanding gray matter pathology in multiple sclerosis: Are we ready to redefine disease pathogenesis? , 2012, BMC Neurology.

[6]  David H. Miller,et al.  Gray matter atrophy is related to long‐term disability in multiple sclerosis , 2008, Annals of neurology.

[7]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[8]  J. Ranjeva,et al.  Individual voxel‐based analysis of brain magnetization transfer maps shows great variability of gray matter injury in the first stage of multiple sclerosis , 2010, Journal of magnetic resonance imaging : JMRI.

[9]  E. Havrdová,et al.  Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort , 2012, Clinical Neurology and Neurosurgery.

[10]  Yi Zhang,et al.  A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images , 2010, Neuroradiology.

[11]  J. Geurts,et al.  Gray matter imaging in multiple sclerosis: what have we learned? , 2011, BMC neurology.

[12]  R. Zivadinov,et al.  Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis , 2009, Multiple sclerosis.

[13]  Michael Brady,et al.  Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images , 2002, NeuroImage.

[14]  Robert Zivadinov,et al.  Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis A case-control study , 2012, NeuroImage.

[15]  D. Ramasamy,et al.  Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  Robert Zivadinov,et al.  Gray matter atrophy and disability progression in patients with early relapsing–remitting multiple sclerosis A 5-year longitudinal study , 2009, Journal of the Neurological Sciences.

[17]  Jeanelle Sheeder,et al.  Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis , 1998 .

[18]  J H Simon,et al.  Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. , 1998, Annals of neurology.

[19]  Roberto Mutani,et al.  Grey Matter Pathology in Multiple Sclerosis , 2005, Journal of neuropathology and experimental neurology.

[20]  P. Matthews,et al.  Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability , 2011, Multiple sclerosis.

[21]  G. Tedeschi,et al.  Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study , 2009, Multiple sclerosis.

[22]  Rohit Bakshi,et al.  Gray matter involvement in multiple sclerosis , 2007, Neurology.

[23]  J. Duda,et al.  Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a , 2000, Multiple sclerosis.

[24]  Peter K. Stys,et al.  Gray matter pathology in (chronic) MS: Modern views on an early observation , 2009, Journal of the Neurological Sciences.

[25]  R. Rudick,et al.  Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS , 2001, Neurology.

[26]  Stephen M. Smith,et al.  A Bayesian model of shape and appearance for subcortical brain segmentation , 2011, NeuroImage.

[27]  References , 1971 .

[28]  R. Rudick,et al.  Gray matter atrophy in multiple sclerosis: A longitudinal study , 2008, Annals of neurology.

[29]  E. Radue,et al.  Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a , 2005, Neurology.

[30]  J. L. Cox,et al.  Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case–control study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[31]  M. Dwyer,et al.  Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis , 2012, American Journal of Neuroradiology.

[32]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[33]  My-Van Au Duong,et al.  Voxel‐based analysis of MTR images: A method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis , 2004, Journal of magnetic resonance imaging : JMRI.

[34]  G. Molenberghs.  Applied Longitudinal Analysis , 2005 .

[35]  E. Havrdová,et al.  Early predictors of non‐response to interferon in multiple sclerosis , 2012, Acta neurologica Scandinavica.

[36]  R. Zivadinov,et al.  I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy , 2007, Multiple sclerosis.

[37]  Massimo Filippi,et al.  Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. , 2009, Archives of neurology.

[38]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 2011, Neurology.

[39]  Massimo Filippi,et al.  Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. , 2002, AJNR. American journal of neuroradiology.

[40]  Chiara Romualdi,et al.  Cortical atrophy is relevant in multiple sclerosis at clinical onset , 2007, Journal of Neurology.

[41]  R. Henry,et al.  Regional grey matter atrophy in clinically isolated syndromes at presentation , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[42]  Robert Zivadinov,et al.  Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. , 2006, Archives of neurology.

[43]  J. Geurts,et al.  Grey matter pathology in multiple sclerosis , 2006, Acta neurologica Scandinavica. Supplementum.

[44]  C. Lucchinetti,et al.  Meningeal and cortical grey matter pathology in multiple sclerosis , 2012, BMC Neurology.

[45]  M. Calabrese,et al.  The predictive value of gray matter atrophy in clinically isolated syndromes , 2011, Neurology.